These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24391204)

  • 21. Fluoroquinolone resistance in Salmonella typhi and S. paratyphi A in Bangalore, India.
    Joshi S; Amarnath SK
    Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):308-10. PubMed ID: 16950486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro antibacterial activity of levofloxacin against hospital isolates: a multicentre study.
    Soussy CJ; Cluzel M; Ploy MC; Kitzis MD; Morel C; Bryskier A; Courvalin P
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():43-50. PubMed ID: 10404337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
    Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced fluoroquinolone susceptibility in Salmonella enterica isolates from travelers, Finland.
    Lindgren MM; Kotilainen P; Huovinen P; Hurme S; Lukinmaa S; Webber MA; Piddock LJ; Siitonen A; Hakanen AJ
    Emerg Infect Dis; 2009 May; 15(5):809-12. PubMed ID: 19402977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of plasmid-mediated quinolone and oxyimino-cephalosporin resistance mechanisms in Uruguayan Salmonella enterica isolates from 2011-2013.
    Cordeiro NF; Nabón A; García-Fulgueiras V; Álvez M; Sirok A; Camou T; Vignoli R
    J Glob Antimicrob Resist; 2016 Sep; 6():165-171. PubMed ID: 27530862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chromosomal and plasmid-mediated fluoroquinolone resistance in human Salmonella enterica infection in Ghana.
    Acheampong G; Owusu M; Owusu-Ofori A; Osei I; Sarpong N; Sylverken A; Kung HJ; Cho ST; Kuo CH; Park SE; Marks F; Adu-Sarkodie Y; Owusu-Dabo E
    BMC Infect Dis; 2019 Oct; 19(1):898. PubMed ID: 31660876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contamination of chicken meat with Salmonella enterica Serovar Haardt with nalidixic acid resistance and reduced fluoroquinolone susceptibility.
    Lee K; Lee M; Lim J; Jung J; Park Y; Lee Y
    J Microbiol Biotechnol; 2008 Nov; 18(11):1853-7. PubMed ID: 19047832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.
    Fuchs PC; Barry AL; Brown SD
    Antimicrob Agents Chemother; 1996 Jul; 40(7):1633-9. PubMed ID: 8807053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin.
    Knapp JS; Hale JA; Neal SW; Wintersheid K; Rice RJ; Whittington WL
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2442-5. PubMed ID: 8585723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
    Biedenbach DJ; Toleman M; Walsh TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):13-21. PubMed ID: 16290025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is nalidixic acid screening still valid for the detection of reduced susceptibility of fluoroquinolone with Salmonella Typhi?
    Irfan S; Jabeen K; Jilani UA; Ahmed B; Mehraj J; Ahsan T; Zafar A
    J Infect Dev Ctries; 2012 Oct; 6(10):700-3. PubMed ID: 23103891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nalidixic acid screening test in detection of decreased fluoroquinolone susceptibility in Salmonella typhi isolated from blood.
    Zafar A; Ibrahim NG; Ahsan T; Abbas Z; Zaidi A; Hasan R
    J Coll Physicians Surg Pak; 2005 Jul; 15(7):413-7. PubMed ID: 16197870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in antimicrobial susceptibility in a population of Salmonella enterica serovar Dublin isolated from cattle in Japan from 1976 to 2005.
    Akiba M; Nakaoka Y; Kida M; Ishioka Y; Sameshima T; Yoshii N; Nakazawa M; Uchida I; Terakado N
    J Antimicrob Chemother; 2007 Dec; 60(6):1235-42. PubMed ID: 17956907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activities of 11 fluoroquinolones against 816 non-typhoidal strains of Salmonella enterica isolated from Finnish patients with special reference to reduced ciprofloxacin susceptibility.
    Kotilainen P; Pitkänen S; Siitonen A; Huovinen P; Hakanen AJ
    Ann Clin Microbiol Antimicrob; 2005 Sep; 4():12. PubMed ID: 16143044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of doxycycline MIC and disk diffusion interpretive breakpoints and revision of tetracycline breakpoints for Streptococcus pneumoniae.
    Dallas SD; McGee L; Limbago B; Patel JB; McElmeel ML; Fulcher LC; Lonsway DR; Jorgensen JH
    J Clin Microbiol; 2013 Jun; 51(6):1798-802. PubMed ID: 23554197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics of Resistance Mechanisms and Molecular Epidemiology of Fluoroquinolone-Nonsusceptible
    Okanda T; Haque A; Ehara T; Huda Q; Ohkusu K; Miah RA; Matsumoto T
    Microb Drug Resist; 2018 Dec; 24(10):1460-1465. PubMed ID: 29894282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quinolone resistance phenotype and genetic characterization of Salmonella enterica serovar Pullorum isolates in China, during 2011 to 2016.
    Guo X; Wang H; Cheng Y; Zhang W; Luo Q; Wen G; Wang G; Shao H; Zhang T
    BMC Microbiol; 2018 Dec; 18(1):225. PubMed ID: 30587131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.